Online Training 2015 - Tougher U.S. FDA cGMP Compliance Audits - When You're Not Ready - By Compliance Global Inc

Overview
There is an on-going major shift in the emphasis of Federal Drug Administration cGMP audits.
These changes in focus have a major impact on individual compliance objectives, efforts and measurements of success. The Agency has come under increasing negative publicity due to multiple drug recalls and pulling of product off the market, importation of tainted foods, lead based paint in toys, and recent public concern over insufficient oversite of new product introductions (and grandfathered product) by means of the 510(k) system.
Business continues to "shoot itself in the foot", including once highly respected companies. All this affects the Agency's approach to audits and their expectations for companies. They also use GMP compliance audits to drive companies to do much of their work for them. There will be no return to the past. Rather than be caught unprepared, proactively address these trends, and start to address areas of known deficiencies.
Why Should You Attend
The FDA says it's getting tougher. Recent audits and other enforcement actions indicate that's true. The past ways of doing things is not acceptable. The Agency continues to use high-profile cases to drive compliance to smaller companies and suppliers.
Recent events in regulated industries indicate a public's growing dissatisfaction with what they view as a lack of oversight of business by regulatory agencies, including the FDA. "Business as usual" is unacceptable. Recently several once 'model' companies have received multi-million dollar fines, with one facing criminal charges.
Don't let you or your company be caught off guard by these major shifts in emphasis. Modify your internal audits to get 'in sync' with the FDA's shift in focus. Put in place a system to address areas of known deficiencies for FDA review.
Areas Covered in this Webinar
This webinar will evaluate the chief areas of an FDA CGMP compliance audit to see actual and anticipated changes in emphasis based on this new regulatory climate. We will also discuss proven methods to prove to the FDA that known company cGMP deficiencies should not be a major concern to the Agency, and which may 'eliminate' the possibility of a deserved Warning Letter.
Learning Objectives
Key cGMP issues
Avoid complacency from past "good" FDA/ ISO auditing
The desired response
How to respond now ? where to shift focus first
Where to direct scarce resources; A risk-based phased approach
How to address known problem areas during an Audit
Prove ‘in control’
Maintain ‘the edge’
Who Will Benefit
Senior Management in Drugs, Devices, Biologics, Dietary Supplements
QA Personnel
RA Personnel
R&D Staff
Engineering Professionals
Production Staff
Operations Professionals
Consultants
Level:
Beginner
For more detail please click on this below link:
https://www.complianceglobal.us/product/700246
Email: referrals-AT-complianceglobal.us
Toll Free: +1-844-746-4244
Tel: +1-516-900-5515